Skip to main content
. Author manuscript; available in PMC: 2012 Aug 14.
Published in final edited form as: Br J Haematol. 2010 Jul 7;150(4):428–437. doi: 10.1111/j.1365-2141.2010.08264.x

Table V.

Patients with peripheral neuropathy on treatment.

Dose group Neuropathy history Last dose of tanespimycin Last dose of bortezomib Onset date Worst grade on treatment
340 mg/m2 Mild PN in the past 12 months/no painful PN Day 4, stopped due to elevated LFTs but continued bortezomib on days 8 and 11 Day 11 Day 13 Grade 3 PN
340 mg/m2 Mild PN in the past 12 months/no painful PN Day 379, administered weekly due to patient decision Day 379, administered weekly due to patient decision Day 92 Grade 1 PN
340 mg/m2 Mild painful PN in the past 12 months Day 8, discontinued due to DIC Day 8, discontinued due to DIC Day 17 Grade 2 worsening sensory PN
50 mg/m2 Moderate PN in the past 12 months/no painful PN Crossed over to high dose on day 85 (cycle 5), continued up to day 403 (cycle 19) Dose reduced to 1·0 mg/m2 bortezomib on day 4 due to grade 3 hypotension and continued up to day 403 (cycle 19) Day 64 Grade 1 PN
50 mg/m2 Mild PN in the past 12 months/no painful PN Crossed over to high dose on day 92, continued receiving up to day 466 (cycle 22) Continued receiving 1·3 mg/m2 bortezomib up to day 466 (cycle 22) Day 372 Grade 1 neuralgia, painful PN
50 mg/m2 Mild painful PN in the past 12 months Continued up to day 53 Continued up to day 53 Day 42 Grade 2 PN

DIC, disseminated intravascular coagulation; LFT, liver function test; PN, peripheral neuropathy.